Genomic Health Inc (GHDX)

30.98
NASDAQ : Health Care
Prev Close 30.85
Day Low/High 30.74 / 31.05
52 Wk Low/High 26.37 / 33.97
Avg Volume 96.30K
Exchange NASDAQ
Shares Outstanding 34.65M
Market Cap 1.07B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score® Test In Predicting Outcomes Across Patient Populations At ESMO 2017

Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score® Test In Predicting Outcomes Across Patient Populations At ESMO 2017

New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive Disease and Experience Excellent Five-year Survival without Chemotherapy

Genomic Health Continues To Pioneer Genomic-based Cancer Diagnostics With Multiple Presentations At ESMO 2017 Congress

Genomic Health Continues To Pioneer Genomic-based Cancer Diagnostics With Multiple Presentations At ESMO 2017 Congress

New Data Reinforce Unmatched Value of the Oncotype DX Breast Recurrence Score® Test to Examine Tumor Biology Across Patient Populations

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer

Oncotype DX® Test Endorsed for Guiding Treatment Decisions on Adjuvant Chemotherapy Both in Node-negative and in Node-positive Disease

Genomic Health Presents Data Further Demonstrating Ability Of Oncotype DX® Tests To Optimize Outcomes In Patients Across Cancer Types

Data from Eight Oncotype DX Studies Across Breast, Prostate and Kidney Cancers Presented at 2017 American Society of Clinical Oncology Annual Meeting

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Announces Presentation Of Eight Oncotype DX® Studies At The 2017 American Society Of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types

Presentations in Breast and Prostate Cancers Highlight Ability of Tests to Answer Critical Clinical Questions and Optimize Treatment Outcomes

Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented At AUA And Published In Urology Establish Test's Ability To Increase Use And Persistence On Active Surveillance In Prostate Cancer Patients

Additional Oncotype DX GPS Test Study Results Represent First-ever Prospective Validation of a Tissue-based Molecular Marker in Prostate Cancer

Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease

With New Data Presented at American Urological Association 2017 Annual Meeting, the GPS Test Becomes the Only Prostate Cancer Genomic Test Validated to Predict Both Near-term Adverse Pathology and Long-term Outcomes

Genomic Health Announces Upcoming Presentation Of Four Oncotype DX® Studies Including New Validation On Its Ability To Predict Prostate Cancer-specific Death And Metastases

Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes

Oncotype DX® Predicts 10-year Risk Of Developing Metastatic Prostate Cancer In Low- And Intermediate-risk Patients

Designated One of the 'Best Posters' by EAU, Results Highlight Expanded Value of Genomic Prostate Score™ in Assessing Risk and Long-term Outcomes in Patients Across Stages of Disease

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Published Outcomes Results From SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based On Oncotype DX® Results

A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence Score® Results

Multiple Presentations At 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact Of Oncotype DX Breast Recurrence Score® In Reducing Burden And Cost Of Chemotherapy

New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

TheStreet Quant Rating: C (Hold)